awmsg logo



dexamethasone (Ozurdex®)


Reference No. 1623

Publication date:
13/01/2015


Appraisal information

dexamethasone (Ozurdex®) intravitreal implant


Company: Allergan Ltd
BNF category: Eye
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 09/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA349) NICE GUIDANCE ISSUED JULY 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) In the absence of a submission from the holder of the marketing authorisation, dexamethasone (Ozurdex®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
Statement of Advice (SOA)
Download